Diaformin (metformin) tablets 500 mg. №60

$9.00

Manufacturer: Ukraine

Purpose: Reduces blood sugar levels in type 2 diabetes through improved insulin sensitivity.

SKU: MED57730 Category:

Description

Diaformin (metformin) tablets 500 mg. №60

Ingredients:

Each tablet contains 500 mg of metformin hydrochloride.

Dosage:

The usual starting dose is one tablet 500 mg once daily with the evening meal. Dosage may be adjusted based on blood glucose levels.

Indications:

Diaformin tablets are indicated for the management of type 2 diabetes mellitus. It helps to control blood sugar levels and may prevent complications of diabetes.

Contraindications:

Do not use Diaformin if you have severe kidney disease or metabolic acidosis. It is important to consult a healthcare provider before starting this medication.

Directions:

Take Diaformin tablets exactly as prescribed by your doctor. Do not crush or chew the tablets; swallow them whole with a glass of water.

Scientific Evidence:

Numerous studies have shown the efficacy of metformin in the management of type 2 diabetes. Research published in the Journal of Clinical Endocrinology & Metabolism demonstrated that metformin significantly reduces hemoglobin A1c levels, indicating improved long-term glucose control.

Additional Information:

It is important to monitor kidney function regularly while taking Diaformin. This medication may cause gastrointestinal side effects such as nausea and diarrhea, which usually improve with continued use.

Metformin, the active ingredient in Diaformin, works by decreasing glucose production in the liver and improving insulin sensitivity in the body’s tissues. This helps to lower blood sugar levels and control diabetes. Additionally, metformin has been shown to have positive effects on lipid profiles, reducing LDL cholesterol and triglycerides.

Clinical trials have compared metformin with other antidiabetic medications and have consistently shown its effectiveness in reducing blood glucose levels and improving overall glycemic control. A study published in Diabetes Care found that metformin was associated with a lower risk of cardiovascular events compared to other oral antidiabetic drugs.